Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

BACKGROUND: Few studies have investigated the safety and efficacy of anti-PD-(L)1 antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge about the influence of baseline clinical and analytical factors on therapy outcomes is scarce. PATIENTS AND METHODS: We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Bañobre, J., Molina-Díaz, A., Fernández-Calvo, O., Fernández-Núñez, N., Medina-Colmenero, A., Santomé, L., Lázaro-Quintela, M., Mateos-González, M., García-Cid, N., López-López, R., Vázquez, S., Anido-Herranz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980066/
https://www.ncbi.nlm.nih.gov/pubmed/33740735
http://dx.doi.org/10.1016/j.esmoop.2021.100090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980066/
https://www.ncbi.nlm.nih.gov/pubmed/33740735
http://dx.doi.org/10.1016/j.esmoop.2021.100090

Ejemplares similares